Laboratory tests for patients with ileal pouch-anal anastomosis: Clinical utility in predicting, diagnosing, and monitoring pouch disorders

American Journal of Gastroenterology

Volumn 104, Issue 10, 2009, Pages 2606-2615

  Navaneethan, Udayakumar ^a   Shen, Bo ^a  

^a Pouchitis Clinic

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYANOCOBALAMIN; HEMOGLOBIN; LACTOFERRIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PYRUVATE KINASE; RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ADENOMATOUS POLYP; ANASTOMOSIS; BACTERIUM CULTURE; BONE METABOLISM; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DYSPLASIA; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FECES CULTURE; GENETIC POLYMORPHISM; GENOTYPE; HEMATOCRIT; HUMAN; HYDROGEN BREATH TEST; ILEITIS; ILEUM POUCH; INFLAMMATION; IRON DEFICIENCY; LABORATORY TEST; LIVER FUNCTION TEST; MONITORING; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEROLOGY; STRATIFICATION; ULCERATIVE COLITIS; CLOSTRIDIUM INFECTION; COLON POUCH; GENETIC MARKER; MICROBIOLOGY; POSTOPERATIVE COMPLICATION; PROCTOCOLECTOMY; RISK FACTOR;

BIOLOGICAL MARKERS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS, ULCERATIVE; COLONIC POUCHES; DIAGNOSIS, DIFFERENTIAL; GENETIC MARKERS; HUMANS; POSTOPERATIVE COMPLICATIONS; POUCHITIS; PROCTOCOLECTOMY, RESTORATIVE; RISK FACTORS;

EID: 70350516094     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.392     Document Type: Review

References (96)

1. Fazio VW, Ziv Y, Church JM et al. Ileal pouch-anal anastomosis: complications and function in 1005 patients. Ann Surg 1995; 222:120-127
2. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994; 107:1856-1860
3. Coffey JC, Winter DC, Neary P et al. Quality of life after ileal pouch-anal anastomosis: an evaluation of diet and other factors using the Cleveland Global Quality of Life instrument. Dis Colon Rectum 2002; 45:30-38
4. Stocchi L, Pemberton JH. Pouch and pouchitis. Gastroenterol Clin North Am 2001; 30:223-241
5. Penna C, Tiret E, Kartheuser A et al. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br J Surg 1993; 80:765-767 (Pubitemid 23197736)
6. Tjandra JJ, Fazio VW, Church JM et al. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg 1993; 165:322-325
7. Shen B, Fazio VW, Remzi FH et al. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch-anal anastomosis. Am J Gastroenterol 2005; 100:93-101
8. Shen B, Achkar JP, Connor JT et al. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum 2003; 46:748-753
9. Sandborn WJ, Tremaine WJ, Batts KP et al. Pouchitis after ileal pouchanal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 1994; 69:409-415
10. Heuschen UA, Allemeyer EH, Hinz G et al. Diagnosing pouchitis: comparative validation of two scoring systems in routine follow-up. Dis Colon Rectum 2002; 45:776-786
11. Moskowitz RL, Shepherd NA, Nicholls RJ. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis 1986; 1:167-174
12. Stallmach A, Sch ä fer F, Hoff mann S et al. Increased state of activation of CD4 positive T cells and elevated interferon gamma production in pouchitis. Gut 1998; 43:499-505
13. Thomas PD, Forbes A, Nicholls RJ et al. Altered expression of the lymphocyte activation markers CD30 and CD27 in patients with pouchitis. Scand J Gastroenterol 2001; 36:258-264
14. Goldberg PA, Herbst F, Beckett CG et al. Leukocyte typing, cytokine expression, and epithelial turnover in the ileal pouch in patients with ulcerative colitis and familial adenomatous polyposis. Gut 1996; 38:549-553
15. Casini-Raggi V, Kam L, Choung YJ et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995; 154:2434-2440
16. Danis VA, Millington M, Hyland V et al. Cytokine production by normal human monocytes-inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1RA) gene polymorphism. Clin Exp Immunol 1995; 99:303-310
17. Brett PM, Yasuda N, Yiannakou JY et al. Genetic and immunological markers in pouchitis. Eur J Gastroenterol Hepatol 1996; 8:951-955
18. Carter MJ, Di Giovine FS, Cox A et al. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology 2001; 121:805-811
19. Aisenberg J, Legnani PE, Nilubol N et al. Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol 2004; 99:432-441
20. Hampe J, Grebe J, Nikolaus S et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002; 359:1661-1665
21. Meier CB, Hegazi RA, Aisenberg J et al. Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor? Inflamm Bowel Dis 2005; 11:965-971
22. Lammers KM, Ouburg S, Morré SA et al. Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitis. World J Gastroenterol 2005; 11:7323-7329
23. Heuschen G, Leowardi C, Hinz U et al. Differential expression of toll-like receptor 3 and 5 in ileal pouch mucosa of ulcerative colitis patients. Int J Colorectal Dis 2007; 22:293-301
24. Sandborn WJ, Landers CJ, Tremaine WJ et al. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996; 71:431-436
25. Vecchi M, Bianchi MB, Sinico RA et al. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: sensitivity, specificity and recognition of putative antigens. Digestion 1994; 55:34-39
26. Vecchi M, Bianchi MB, Calabresi G et al. Long-term observation of the perinuclear anti-cytoplasmic antibody status in ulcerative colitis patients. Scand J Gastroenterol 1998; 33:170-173
27. Aisenberg J, Wagreich J, Shim J et al. Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis. Dig Dis Sci 1995; 40:1866-1872
28. Yang P, Oresland T, Jarnerot G et al. Perinuclear antineutrophil cytoplasmic antibody in pouchitis after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Scand J Gastroenterol 1996; 31:594-598
29. Yasuda N, Thomas P, Ellis H et al. Perinuclear antineutrophil cytoplasmic antibodies in ulcerative colitis after restorative proctocolectomy do not correlate with the presence of pouchitis. Scand J Gastroenterol 1998; 33:509-513
30. Vecchi M, Gionchetti P, Bianchi MB et al. p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. Lancet 1994; 344:886-887
31. Sandborn WJ, Landers CJ, Tremaine WJ et al. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol 1995; 90:740-746
32. Kaditis AG, Perrault J, Sandborn WJ et al. Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr 1998; 26:386-392
33. Fleshner PR, Vasiliauskas EA, Kam LY et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouchanal anastomosis. Gut 2001; 49:671-677
34. Fleshner P, Ippoliti A, Dubinsky M et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2008; 6:561-568
35. Quinton JF, Sendid B, Reumaux D et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42:788-791
36. Peeters M, Joossens S, Vermeire S et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96:730-734
37. Norman GL. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease. Clin Applied Immunol Rev 2001; 2:45-63
38. Melmed GY, Fleshner PR, Bardakcioglu O et al. Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2008; 51:100-108
39. Dendrinos KG, Becker JM, Stucchi AF et al. Anti-Saccharomyces cerevisiae antibodies are associated with the development of postopera tive fistulas following ileal pouch-anal anastomosis. J Gastrointest Surg 2006; 10:1060-1064
40. Klebl FH, Bataille F, Bertea CR et al. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis 2003; 9:302-307
41. Tang L, Boone J, Moore L et al. Clinical significance of stool ASCA in disorders of the ileal pouch. Inflamm Bowel Dis 2008; 12:S2 (Abstract)
42. Lodes MJ, Cong Y, Elson CO et al. Bacterial flagellin is a dominant antigen in Crohn's disease. J Clin Invest 2004; 113:1296-1306
43. Targan SR, Landers CJ, Yang H et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005; 128:2020-2028
44. Hayashi F, Smith KD, Ozinsky A et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099-1103
45. Means TK, Hayashi F, Smith KD et al. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 2003; 170:5165-5175
46. Toiyama Y, Araki T, Yoshiyama S et al. The expression patterns of toll. Surg Today 2006; 36:287-290
47. Page C. Platelets as inflammatory cells. Immunopharmacology 1989; 17:51-59
48. Klinger MH. Platelets and inflammation. Anat Embryol (Bed) 1997; 196:1-11
49. Talstad I, Rootwelt K, Gjone E. Th rombocytosis in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1973; 8:135-138
50. Collins CE, Cahill MR, Newland AC et al. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994; 106:840-845
51. Simi M, Leardi S, Tabano MT et al. Raised plasma concentrations of platelet factor 4 (PF4) in Crohn's disease. Gut 1987; 28:336-338
52. Vrij AA, Rijken J, Van Wersch JW et al. Platelet factor 4 and beta-thromboglobulin in inflammatory bowel disease and giant cell arteritis. Eur J Clin Invest 2000; 30:188-194
53. Danese S, delaMotte C, Sturm A et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 2003; 124:1249-1264 (Pubitemid 36531801)
54. Okon A, Dubinsky M, Vasiliauskas EA et al. Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis. Am Surg 2005; 71:821-826
55. Fleshner P, Ippoliti A, Dubinsky M et al. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2007; 5:952-958
56. Hoda KM, Collins JF, Knigge KL et al. Predictors of pouchitis after ileal pouch-anal anastomosis: a retrospective review. Dis Colon Rectum 2008; 51:554-560
57. Penna C, Dozois R, Tremaine W et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38:234-239 (Pubitemid 26046819)
58. Galvez J, Rodriguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol Nutr Food Res 2005; 49:601-608
59. Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980; 21:793-798
60. Luhrs H, Gerke T, Muller JG et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002; 37:458-466
61. Kinoshita M, Suzuki Y, Saito Y. Butyrate reduces colonic paracellular permeability by enhancing PPAR gamma activation. Biochem Biophys Res Commun 2002; 293:827-831
62. Segain JP, Raingeard dlB, Bourreille A et al. Butyrate inhibits inflammatory responses through NF kappa B inhibition: implications for Crohn's disease. Gut 2000; 47:397-403
63. Roediger WE. The colonic epithelium in ulcerative colitis: an energy defi-ciency disease? Lancet 1980; 2:712-715
64. Finnie IA, Taylor BA, Rhodes JM. Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate metabolism. Gut 1993; 34:1552-1558
65. Ahmad MS, Krishnan S, Ramakrishna BS et al. Butyrate and glucose metabolism by colonocytes in experimental colitis in mice. Gut 2000; 46:493-499
66. Chapman MA, Grahn MF, Hutton M et al. Butyrate metabolism in the terminal ileal mucosa of patients with ulcerative colitis. Br J Surg 1995; 82:36-38
67. Clausen MR, Tvede M, Mortensen PB. Short-chain fatty acids in pouch contents from patients with and without pouchitis after ileal pouch-anal anastomosis. Gastroenterology 1992; 103:1144-1153
68. Sagar PM, Taylor BA, Godwyn P et al. Acute pouchitis and deficiencies of fuel. Dis Colon Rectum 1995; 38:488-493
69. Hove H, Mortensen PB. Short-chain fatty acids in the nonadapted and adapted pelvic ileal pouch. Scand J Gastroenterol 1996; 31:568-574
70. Renom G, Bulois P, Hafraoui S et al. Simple gas chromatography analysis of faecal butyrate: application to patients at risk of pouchitis. Clin Chem Lab Med 2001; 39:15-19
71. De Preter V, Bulteel V, Suenaert P et al. Pouchitis, similar to active ulcerative colitis, is associated with impaired butyrate oxidation by intestinal mucosa. Inflamm Bowel Dis 2009; 15:335-340
72. Wischmeyer P, Pemberton JH, Phillips SF. Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study. Mayo Clin Proc 1993; 68:978-981
73. Sandborn WJ, Tremaine WJ, Batts KP et al. Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis. Dig Dis Sci 1995; 40:1474-1483
74. Kuisma J, Nuutinen H, Luukkonen P et al. Long term metabolic consequences of ileal pouch-anal anastomosis for ulcerative colitis. Am J Gastroenterol 2001; 96:3110-3116
75. M'koma AE. Serum biochemical evaluation of patients with functional pouches ten to 20 years after restorative proctocolectomy. Int J Colorectal Dis 2006; 21:711-720
76. Tillet WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of the pneumococcus. J Exp Med 1930; 52:561-571
77. Tall AR. C-reactive protein reassessed. N Engl J Med 2004; 350:1450-1452
78. Young B, Gleeson M, Cripps AW. C-reactive protein: a critical review. Pathology 1991; 23:118-124
79. Pepys MB, Druguet M, Klass HJ et al. Immunological studies in inflammatory bowel disease. In: Porter R, Knight J (eds). Immunology of the Gut, Ciba Foundation Symposium. Elsevier/Excerpta Medica/North Holland: Amsterdam, 1977, pp. 283-297
80. Saverymuttu SH, Hodgson HJ, Chadwick VS et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986; 27:809-813
81. Desai D, Faubion WA, Sandborn WJ. Review article: biological markers in inflammatory bowel disease. Aliment Pharmacolther 2007; 25:247-255
82. Biancone L, Fantini M, Tosti C et al. Fecal alpha-1-antitrypsin clearance as a marker of clinical relapse in 1289 patients with Crohn's disease of the distal ileum. Eur J Gastroenterol Hepatol 2003; 15:261-266
83. Steinbakk M, Naess-Andresen C-F, Lingaas E et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990; 336:763-765
84. Rø Seth AG, Fagerhol MK, Aadland E et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27:793-798
85. Fagerhol MK, Dale I, Anderson I. Release and quantification of leukocyte derived protein (L1). Scand J Haematol 1980; 24:393-398
86. Tibble J, Teahon K, Thjodleifsson B et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47:506-513
87. Thomas P, Rihani H, R ø seth A et al. Assessment of ileal pouch inflammation by single stool calprotectin assay. Dis Colon Rectum 2000; 43:214-220
88. Johnson MW, Maestranzi S, Duff y AM et al. Fecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol 2008; 20:174-179
89. Buderus S, Boone J, Lyerly D et al. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci 2004; 49:1036-1039
90. Angriman I, Scarpa M, D'Inc à R et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007; 381:63-68
91. Parsi M, Shen B, Achkar J et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004; 126:1280-1286 (Pubitemid 38552792)
92. Lim M, Gonsalves S, The kkinkattil D et al. The assessment of a rapid noninvasive immunochromatographic assay test for fecal lactoferrin in patients with suspected inflammation of the ileal pouch. Dis Colon Rectum 2008; 51:96-99
93. Parsi MA, Ellis JJ, Lashner BA. Cost-Effectiveness of quantitative fecal lactoferrin assay for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. J Clin Gastroenterol 2008; 42:799-805
94. Hardt PD, Mazurek S, Toepler M et al. Fecal tumor M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91:980-984
95. Walkowiak J, Banasiewicz T, Krokowicz P et al. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scand J Gastroenterol 2005; 40:1493-1494
96. Tibble JA, Sigthorsson G, Bridger S et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119:15-22.